Immune System Related Kidney Disease

Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT00001979
Collaborator
(none)
2,000
1

Study Details

Study Description

Brief Summary

Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders.

This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney. It will attempt to provide information about the causes and specific abnormalities associated with autoimmune kidney disease.

Patients with kidney disease as a result of their immune system, and patients with diseases of the immune system who may later develop kidney disease, will be potential subjects for this study.

Patients will undergo a history and physical examination, and standard laboratory test to more closely understand the causes, signs, symptoms, and responses to medication of these diseases. Based on these evaluations the patients may qualify as candidates for other experimental studies. At any time these patients may be asked to submit blood or urine samples for further research.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Study Description:

    This study evaluates participants with known or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other systemic or connective tissue disorders. Participants who have immunologically-mediated diseases with potential for kidney disease will be evaluated as well. Studies will include characterization of the clinical and laboratory features of these disorders, studies of natural history and complications, evaluation of responses to standard treatment. Blood and urine samples will be collected for immunological research conducted under this protocol.

    Objectives:
    • To facilitate the program of research on immunologically-mediated kidney diseases:

    • Better understand rare forms of immunologically-mediated renal disorders, those with atypical renal disease, or those whose renal diseases have not been fully characterized. Enrolled participants will serve as a catalyst for development of new therapeutic interventions.

    Exploratory:
    To conduct further research to fully characterize immunologicallymediated kidney diseases:
    • Development of assays for novel antibodies.

    • Search for additional antibodies involved in the pathogenesis of membranous nephropathy.

    • Assess changes in metabolic and endocrine function during nephrotic state and during remission.

    • Identify disease-causing memory B cells in participants with membranous nephropathy and correlation with membranous nephropathy relapse. Assess biological effects of phospholipase A2-receptor antibody epitope on the isolated memory B-cells.

    • Computational analysis of renal structures which may provide predictive method that would discriminate progressors from non-progressors beyond sclerosis in membranous nephropathy.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Studies of Immunologically-Mediated Kidney Diseases
    Actual Study Start Date :
    Jun 25, 1992

    Arms and Interventions

    Arm Intervention/Treatment
    Patients

    Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.

    Outcome Measures

    Primary Outcome Measures

    1. Provision of biospecimens [ongoing]

      Patients with autoimmune diseases for whom there are no current experimental treatment protocols can be admitted for study and follow-up; they will provide a ready pool of candidates who can be asked to provide blood specimens for ongoing laboratory studies.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    10 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    Male or female participants greater than or equal to 18 years of age and children 10-17 years of age.

    Participants with known, proven, or suspected immunologically-mediated kidney diseases, including but not limited to nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with other systemic or connective tissue disorders.

    Participants who have Immunologically-mediated diseases with the potential for kidney disease.

    Ability of the participant or guardian to understand and the willingness of the participant or guardian to provide written informed consent.

    EXCLUSION CRITERIA:

    Concomitant medical problems which would confound the interpretation of studies of the immunologic kidney disorder.

    Concomitant medical, surgical or other conditions for which inadequate facilities or funds are available to support their care at the NIH.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Investigators

    • Principal Investigator: Meryl A Waldman, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    ClinicalTrials.gov Identifier:
    NCT00001979
    Other Study ID Numbers:
    • 920156
    • 92-DK-0156
    First Posted:
    Jan 21, 2000
    Last Update Posted:
    Aug 23, 2022
    Last Verified:
    Aug 18, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 23, 2022